Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Johnson and Johnson
Colorcon
McKesson
Mallinckrodt

Last Updated: May 27, 2022

Investigational Drug Information for SGS-742


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for SGS-742?

SGS-742 is an investigational drug.

There have been 4 clinical trials for SGS-742. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2019.

The most common disease conditions in clinical trials are Sjogren's Syndrome, Amino Acid Metabolism, Inborn Errors, and Sclerosis. The leading clinical trial sponsors are University of Campania "Luigi Vanvitelli", University of Milan, and University of Modena and Reggio Emilia.

There are forty-two US patents protecting this investigational drug and four hundred and sixty-five international patents.

Recent Clinical Trials for SGS-742
TitleSponsorPhase
A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome PatientsPeking Union Medical College HospitalPhase 1/Phase 2
Colchicine for Amyotrophic Lateral SclerosisCatholic University of the Sacred HeartPhase 2
Colchicine for Amyotrophic Lateral SclerosisIRCCS National Neurological Institute "C. Mondino" FoundationPhase 2

See all SGS-742 clinical trials

Clinical Trial Summary for SGS-742

Top disease conditions for SGS-742
Top clinical trial sponsors for SGS-742

See all SGS-742 clinical trials

US Patents for SGS-742

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGS-742 See Plans and Pricing Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function Pharnext (Paris, FR) See Plans and Pricing
SGS-742 See Plans and Pricing Compositions for preventing and/or treating degenerative disorders of the central nervous system Amicus Therapeutics, Inc. (Cranbury, NJ) See Plans and Pricing
SGS-742 See Plans and Pricing Compositions and methods for neurological diseases Coda Biotherapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
SGS-742 See Plans and Pricing Substituted propane-phosphinic acid compounds Ciba-Geigy Corporation (Ardsley, NY) See Plans and Pricing
SGS-742 See Plans and Pricing Substituted propane-phosphinic acid compounds Ciba-Geigy Corporation (Ardsley, NY) See Plans and Pricing
SGS-742 See Plans and Pricing Substituted propane-phosphinic acid compounds Ciba-Geigy Corporation (Ardsley, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SGS-742

Drugname Country Document Number Estimated Expiration Related US Patent
SGS-742 Australia AU2009242113 2028-04-29 See Plans and Pricing
SGS-742 Brazil BRPI0911874 2028-04-29 See Plans and Pricing
SGS-742 Canada CA2722295 2028-04-29 See Plans and Pricing
SGS-742 China CN102065858 2028-04-29 See Plans and Pricing
SGS-742 China CN104127434 2028-04-29 See Plans and Pricing
SGS-742 Eurasian Patent Organization EA024147 2028-04-29 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Johnson and Johnson
Colorcon
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.